Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1208
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded413    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


Year : 2017  |  Volume : 54  |  Issue : 5  |  Page : 25-30

Liquid biopsy: A potential and promising diagnostic tool for advanced stage non-small cell lung cancer patients

1 Senior Consultant Director of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India
2 Surgical Oncologist, Asian Cancer Institute, Mumbai, India
3 Senior Consultant, Medical Oncology, Fortis Hospital, Mulund, Mumbai, India
4 Associate Professor in Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore and Consultant Medical Oncologist HCG Hospitals, Bangalore, India
5 Professor, Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
6 Director & Head, Department of Oncology & Hematology, Artemis Health Institute, Gurgaon, Haryana, India
7 Senior Consultant, Department of Oncology, Apollo Health City, Apollo Hospitals, Hyderabad, India
8 Consultant Oncologist, Dinanath Mangeshkar Hospital, Pune, India
9 Consultant Molecular Pathologist, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India

Correspondence Address:
Dr. D C Doval
Senior Consultant Director of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijc.IJC_514_17

Rights and Permissions

More than 50% of non-small cell lung cancer (NSCLC) cases harbor an actionable mutation, and molecular testing at different intervals can help in personalized and targeted treatment. Core tissue biopsy and needle biopsy done at the time of diagnosis/disease progression are interventional, time-consuming and can affect the patients adversely. Noninterventional biomarker testing by liquid biopsy promises to revolutionize advanced stage cancer screening. The present report was formulated based on an expert panel meeting of renowned oncologists who gave their opinions for minimally invasive liquid biopsy to detect targetable molecular biomarkers in advanced NSCLC cases. An exhaustive literature search was done to support their recommendations. Clinical utility of minimally invasive liquid biopsy, for detection of molecular biomarkers in advanced stage NSCLC patients, was broadly discussed by the key opinion leaders.


Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow